ACM
IMVT icon

Atika Capital Management’s Immunovant IMVT Stock Holding History

Atika Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-160,000
Closed -$5.17M – 103
2024
Q1 		$5.17M Buy
160,000
+40,000
+33% +$1.46M 0.51% 67
2023
Q4 		$5.06M Sell
120,000
-89,000
-43% -$3.28M 0.68% 57
2023
Q3 		$8.02M Buy
+209,000
New +$4.72M 1.05% 41
2021
Q1 		– Sell
-119,198
Closed -$5.51M – 107
2020
Q4 		$5.51M Buy
119,198
+2,198
+2% +$102K 0.43% 81
2020
Q3 		$4.12M Buy
+117,000
New +$3.52M 0.34% 78

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Atika Capital Management's IMVT Position: Q2 2024 in Review

Atika Capital Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 160,000 shares — an estimated $5.17M sold.

Atika Capital Management first reported a position in IMVT in Q3 2020 and held it in 5 quarters. The position peaked at $8.02M in Q3 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Atika Capital Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Atika Capital Management sold 160,000 Immunovant shares in Q2 2024, an estimated $5.17M.
  • Atika Capital Management first reported a position in Immunovant in Q3 2020 and held it in 5 quarters.
  • Atika Capital Management's Immunovant position peaked at $8.02M in Q3 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Atika Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.